GoodRx

Company GDRX

Last mentioned: Feb 26, 2026

Stories mentioning GoodRx 2

pharma Neutral

Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.

12 sources
pharma Neutral

GoodRx and Schrödinger Report 2025 Results Amid Shifting Pharma Tech Landscape

GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.

3 sources